DGAP-News: INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG

        Print
| Source: EQS Group AG
DGAP-News: INJEX Pharma AG / Key word(s): Miscellaneous
INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG

17.12.2013 / 11:11

---------------------------------------------------------------------

Corporate News: Strategic Financial Group invests in INJEX Pharma AG

Berlin, December 17, 2013 - INJEX Pharma AG anounces, that Fambrinia Ltd.
(Fambrinia) has taken a significant share in the Berlin based company and
has become the largest shareholder in INJEX Pharma AG. Fambrinia holds the
distribution rights for Injex Pharma products in Russia, Kazachstan,
Azerbaijan, Belorussia and Turkmenistan. The respective contracts have been
signed last Friday. The previously signed term sheet between the parties
was already announced in an ad hoc news by INJEX Pharma last week.

Fambrinia subscribes all newly issued ordinary shares of a 10% capital
increase decided by the Executive Board and authorized by the Supervisory
Board. Following this capital increase, the company's share capital rises
from EUR 3,458,000.00 to EUR 3,803,800.00, divided into 3,803,800 shares at
a nominal value of EUR 1.00 per share. The issue price per share is set at
EUR 1.00. The new shares carry full dividend rights from 1 January 2013.
The new shares will be issued in private placement without pre-emptive
rights.

Furthermore, Fambrinia acquires a majority of the shares currently held by
MMB Medical Marketing Berlin GmbH (MMB), so far the major shareholder of
INJEX Pharma AG. MMB will transfer the most of the sales proceeds as a
shareholder loan to INJEX Pharma AG.

The proceeds from this transaction will mainly be used to reduce the
companies liabilities  and to further develop its operations.  Upon
consummation of the transaction, Fambrinia will held 40% of INJEX Pharma
shares and become be the major shareholder, followed by MMB holding 14% of
the shares.

'We are very pleased having attracted Fambrinia as a strategic investor,
who will provide us with growth capital as well as with valuable input for
the future development for our products and applications since Fambrinia is
our distributor for the huge markets in CIS countries.' commented Dr.
Thomas Klaue, CEO of INJEX Pharma AG.  Dr. Peter Heinrich, Chairman of the
Supervisory Board, adds: 'With this transaction, the Management Board,
which took office in last May, has concluded most of the necessary
reorganization and restructuring of INJEX Pharma and can now focus on our
operating business, mainly on the production development and the expansion
of the international partner and distributor network.'

For further information on INJEX Pharma AG and its subsidiaries, please
refer to www.injex.com. For further questions please contact our Investor
Relations team directly:

INJEX Pharma AG
Investor Relations-Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 228
ir@injex.de

INJEX Pharma AG:

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.


End of Corporate News

---------------------------------------------------------------------

17.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                     
Company:     INJEX Pharma AG                                             
             Buckower Damm 114                                           
             12349 Berlin                                                
             Germany                                                     
Phone:       +49 89 24 41 18 - 223                                       
Fax:         +49 89 24 41 18 - 499                                       
E-mail:      ir@injex.de                                                 
Internet:    www.injex.de                                                
ISIN:        DE000A0STYL7                                                
WKN:         A0STYL                                                      
Listed:      Regulierter Markt in Frankfurt (General Standard)           
             Notierung im Regulierten Markt vorgesehen / intended to be  
             listed at Regulated Market                                  
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
245122 17.12.2013